Beacon Securities analyst Doug Cooper thinks the market has so far ignored a series of recent game-changing announcements by medical technology company MedX Health (MedX Health Stock Quote, Chart, News TSXV:MDX).
That scenario, said Cooper in a June 16 update to clients, makes for a prime investment opportunity.
Mississauga, Ontario-based MedX Health is developing non-invasive and cost-effective skin analysis and assessment systems for use by medical professionals. The company’s DermSecure telemedicine platform uses its SIAscopy technology which allows for images to be uploaded and sent to dermatologists for review.
MedX is now through its R&D phase with regulatory approval in 35 countries and has started commercialization.
MedX announced on Monday signing an exclusive distribution agreement to launch SIAscopy on DermSecure in Mexico through what it calls “an aggressive ease-of-access skin scanning/assessment program throughout Mexico” with partner company MedX Mexico.
MedX Mexico said it will be seeking regulatory approval, which it expects will come within the next 60 days, and then commence commercial sales.
According to the company, the opportunity in Mexico is significant, with skin cancer being a very common type of cancer in the country and with MedX’s already-established relationships there.
“MedX Mexico has experience in marketing medical devices and health solutions in the Mexican market, as well as a strong connections with hospitals, major pharmacies and medical clinics which will be a great benefit as it enters into this large market, and we are delighted to be partnering with them,” said Scott Spearn, who, as just announced on Thursday, will be stepping down immediately from the roles of president and CEO of MedX due to family reasons.
On the Mexico deal, Cooper called it, “just the latest in a series of game changing announcements from the company.”
“Yet the stock has yet to react, which we believe creates excellent opportunity for investors. Over the past few months, it has announced new distribution relationships, the imminent commencement of a pharmacy trial in Canada and the closing of a $3.3 million private placement that provided the company with necessary growth capital,” Cooper wrote.
Cooper argued that with its medical device and platform MedX is filling an unmet medical need, where on a global scale melanoma continues to be mis-diagnosed and patients have long wait times to see a dermatologist, a problem as melanoma, if untreated, can become life threatening in as little as six weeks through spread to other parts of the body.
The analyst noted MedX’s Mexican announcement comes on the heels of its exclusive distribution partnership in Brazil (also with a significant skin cancer problem, Cooper says), while on the home front, Cooper said,
“We believe MedX is about to start a trial with a high profile pharmacy chain in Canada. Given the success of the ‘proof of concept’ trial with Boots Pharmacy in Norway, we believe this will not only be successful but will also increase the company’s exposure in the investment community,” Cooper wrote.
The analyst also said he thinks MedX is continuing meaningful conversations with potential partners in the United States and Europe, while also noting there could be an expansion in market opportunity to other conditions such as rosacea, acne and eczema.
With the update, Cooper maintained his “Buy” rating and $0.45 per share target price, which at press time amounted to a projected 12-month return of 233 per cent.